Drugs & Targets FDA approves Keytruda + Padcev for first-line treatment of certain patients with locally advanced or metastatic urothelial cancer April 07, 2023Vol.49 No.14
Drugs & Targets FDA grants full approval indication for Keytruda for certain patients with advanced MSI-H or dMMR solid tumors March 31, 2023Vol.49 No.13
Drugs & Targets Libtayo + chemo approved by EC for first-line treatment of advanced PD-L1-positive NSCLC March 31, 2023Vol.49 No.13
Drugs & Targets Predictive Oncology and Integra Therapeutics form collaboration focused on gene therapy March 31, 2023Vol.49 No.13
Drugs & Targets ArsenalBio’s lead product advances to clinical manufacturing following Thermo Fisher collaboration March 31, 2023Vol.49 No.13
Drugs & Targets FDA releases draft guidance aimed at improving oncology clinical trials for accelerated approval March 24, 2023Vol.49 No.12
Drugs & Targets FDA grants accelerated approval to Zynyz for metastatic or recurrent locally advanced Merkel cell carcinoma March 24, 2023Vol.49 No.12
Drugs & Targets ACS & Winship Cancer Institute partner to accelerate cancer research in Georgia March 24, 2023Vol.49 No.12
Drugs & Targets FDA approves Tafinlar + Mekinist for pediatric patients with low-grade glioma with a BRAF V600E mutation March 17, 2023Vol.49 No.11
Drugs & Targets Prelude Therapeutics to collaborate with BeiGene to evaluate PRT2527 + zanubrutinib in hematologic cancers March 17, 2023Vol.49 No.11
